Introduction
============

The worldwide emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) threatens global efforts to control tuberculosis[@B1][@B2]. Isoniazid (INH) and rifampicin (RFP) are the main components of first-line anti-tuberculosis treatment and are effective drugs for the treatment of tuberculosis[@B3][@B4][@B5]. MDR-TB is resistant to INH and RFP, and the emergence of MDR-TB is placing an increasing burden on South Korea[@B4][@B5][@B6].

*Mycobacterium tuberculosis* can acquire resistance to RFP through mutations in *rpoB*, which encodes the β subunit of RNA polymerase[@B7][@B8][@B9]. Mutations in *rpoC*, which encodes the β′ subunit of RNA polymerase, have also been associated with increased *in vitro* fitness and were overrepresented in MDR-TB isolates from countries with high MDR-TB burdens[@B10][@B11]. One study showed that *M. tuberculosis* isolates harbouring an *rpoB* mutation also carried nonsynonymous mutations in *rpoC* [@B10].

In this study, we investigated *rpoC* mutation patterns in drug-resistant and susceptible *M. tuberculosis* isolates from patients in South Korea to determine the epidemiological relevance of *rpoC* nonsynonymous mutations in a high-incidence setting of MDR- and XDR-TB.

Materials and methods
=====================

1. *Mycobacterial* isolates and susceptibility testing
------------------------------------------------------

Ninety-three *M. tuberculosis* isolates with clinically observed drug resistance were collected at National Masan Hospital and Pusan National University College of Medicine in South Korea and were cultured to determine their susceptibility to anti-tubercular agents ([Table 1](#T1){ref-type="table"}). Each isolate was cultured on Löwenstein-Jensen medium at 37℃ for 3--4 weeks and tested for resistance to critical concentrations of capreomycin (40 µg/mL), ethambutol (2.0 µg/mL), INH (0.2 µg/mL), kanamycin (40 µg/mL), ofloxacin (2 µg/mL), streptomycin (4 µg/mL), pyrazinamide (100 µg/mL, Wayne\'s pyrazinamidase assay[@B12]), and RFP (40 µg/mL). *M. tuberculosis* H37Rv (American Type Culture Collection \[ATCC\] 27294) was used as a positive control in all of the experiments. The following drug-resistant profiles were defined: MDR, resistance to both RFP and INH; MDR-plus, resistance to any of the second-line injectable drugs (INH+RFP+Inj.D) or to any fluoroquinolone drugs (INH+RFP+FQ); XDR, extensively drug-resistant; DR, drug resistance other than MDR (including MDR-plus and XDR); and S, susceptibility to all of the drugs. Sixty-six *M. tuberculosis* isolates were RFP resistant ([Table 1](#T1){ref-type="table"}).

This study was approved by the institutional review board (IRB) at the International Tuberculosis Research Centre, and all subjects signed an informed consent form.

2. Polymerase chain reaction and sequencing of *rpoC*
-----------------------------------------------------

The *rpoC* region (1,730 bp) was amplified by polymerase chain reaction (PCR) using the GeneAmp PCR System 9600 (PerkinElmer, Foster City, CA, USA) with primers 5′-CGAAAACCTCTACCGCGAAC-3′ and 5′-CACGGAAGGAGGACTTGACC-3′[@B10].

Briefly, the PCR parameters were 5 minutes at 95℃, followed by 40 cycles of 45 seconds at 94℃, 45 seconds at 60℃, and 60 seconds at 72℃, with a final extension step at 72℃ for 10 minutes. The PCR products were purified using a QIAEX II Gel Extraction Kit (Qiagen Inc., Mainz, Germany) according to the manufacturer\'s instructions and sequenced using a BigDye Terminator cycle sequencing kit with AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) using primers 5′-CGAAAACCTCTACCGCGAAC-3′ and 5′-CACGGAAGGAGGACTTGACC-3′[@B10]. The nucleotide sequences were analyzed using BioEdit software version 5.0.9.1 (Ibis Biosciences, Carlsbad, CA, USA), Chromas version 2.33 (Technelysium, Brisbane, QLD, Australia, <http://www.technelysium.com.au/chromas.html>), and the Basic Local Alignment Search Tool (BLAST, National Center for Biotechnology Information, Bethesda, MD, USA, <http://blast.ncbi.nlm.nih.gov/Blast.cgi>). Mutations in the *rpoC*-encoding regions were defined as any nucleotide changes that led to translational changes in *RpoC* compared with the RFP-susceptible strain, H37Rv (ATCC 27294).

Results
=======

Ninety-three clinical isolates were included in this study, and all were from South Korean patients. Drug susceptibility testing identified 75 multidrug-resistant isolates: 20 were categorized as MDR-TB, seven were categorized as MDR-plus, 36 were categorized as XDR-TB, and 12 were categorized as DR-TB. Moreover, 66 of the cultured *M. tuberculosis* isolates were found to be RFP-resistant. Eighteen isolates were categorized as S ([Table 1](#T1){ref-type="table"}).

*rpoC* PCR products were amplified from 93 isolates and sequenced. Fifteen different types of mutations were identified in 24 isolates (24/93, 25.8%), all of which were resistant to both INH and RFP. The *rpoC* mutation rate of the MDR- and XDR-TB isolates was 37.0% (10/27) and 38.9% (14/36), respectively ([Table 2](#T2){ref-type="table"}).

Single mutations (22/24, 91.7%) and multiple mutations (2/24, 8.3%) in the *rpoC* region were identified, but no deletion nor insertion mutations were detected in any of the isolates. No mutations were identified in the *rpoC* region of any drug-susceptible strains. A mutation at codon 452 (nt 1356) was the most common mutation (7/24, 29.2%) and a mutation at codon 531 (nt 1594), which is the most frequently mutated nucleotide in *rpoB* , was also detected in these isolates ([Supplementary Table S1](#S1){ref-type="supplementary-material"})[@B7][@B8][@B9]. Twelve different mutation sites (at codon 281 \[nt 843\], 416 \[nt 1249\], 434 \[nt 1302\], 446 \[nt 1338\], 561 \[nt 1683\], 575 \[nt 1726\], 581 \[nt 1745\], 728 \[nt 2186\], 747 \[nt 2242\], 801 \[nt 2403\], 812 \[nt 2437\], and 813 \[nt 2441\]) are reported for the first time in this study[@B10][@B11]; these new mutations are shown in [Table 3](#T3){ref-type="table"}.

Discussion
==========

RFP is one of the principal first-line drugs used in combination chemotherapy for tuberculosis, and RFP resistance is a valuable surrogate marker of MDR-TB. Over 90% of RFP-resistant clinical *M. tuberculosis* isolates possess genetic alterations in *rpoB*[@B2][@B8].

*rpoC* encodes the β′ subunit of RNA polymerase, and Comas et al.[@B11] suggested that the acquisition of particular mutations in *rpoC* by RFP-resistant *M. tuberculosis* strains leads to the emergence of MDR strains with high fitness over time. Additionally, de Vos et al.[@B10] showed that nonsynonymous mutations in the *rpoC* region were prevalent among RFP-resistant isolates in a South African high-burden setting; these mutations were strongly associated with the transmission of RFP-resistant strains.

*rpoC* mutations have not been studied in South Korea; thus, we investigated the *rpoC* mutation patterns in drug-resistant and susceptible *M. tuberculosis* isolates from patients in South Korea. Fifteen different types of mutations were identified, 12 of which were reported for the first time in this study ([Table 3](#T3){ref-type="table"})[@B10][@B11]. A mutation at codon 452 was the most common mutation (7/24, 29.2%), and a mutation at codon 531, which is the most frequently mutated nucleotide in *rpoB*, was also detected in these isolates ([Supplementary Table S1](#S1){ref-type="supplementary-material"})[@B7][@B8][@B9].

Mutations were found only in the MDR-TB isolates and no *rpoC* mutations were identified in any of the drug-susceptible strains ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

Therefore, we suggest that *rpoC* mutations could be used DNA-based diagnosis for detection of INH and RFP drug resistance; however, more extensive studies on larger collections of isolates are needed.

In summary, 15 different types of mutations were identified. Substitutions in a single nucleotide were the most common mutation found (22/24, 91.7%), and mutations were found only in dual INH- and RFP-resistant isolates in this study.
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Supplementary material can be found in the journal homepage (<http://www.e-trd.org>).

[Supplementary Table S1](#S1){ref-type="supplementary-material"}. Mutations detected in the *rpoB* gene of 80 isolates.

###### Supplementary Table S1

Mutations detected in the *rpoB* gene of 80 isolates

###### Drug resistance profiles of 93 *Mycobacterium tuberculosis* isolates

![](trd-81-222-i001)

  No.   Drug resistance                             Drug resistance profile   No.   Drug resistance                             Drug resistance profile
  ----- ------------------------------------------- ------------------------- ----- ------------------------------------------- -------------------------
  1     SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       48    None detected                               S
  2     SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       49    CPM                                         DR
  3     SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR                       50    INH, RFP, OFX, MFX, PZA                     MDR
  4     INH, RFP, CPM, KM, PZA                      MDR                       51    INH, RFP, KM, OFX, MFX, PZA                 XDR
  5     SM, INH, RFP, EMB, OFX, MFX, PZA            MDR                       52    INH, RFP                                    MDR
  6     INH, RFP, OFX, MFX                          MDR                       53    SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR
  7     SM, INH, RFP, EMB, CPM, KM, MFX, PZA        XDR                       54    SM, INH, RFP, EMB, OFX, PZA                 XDR
  8     SM, INH, RFP, MFX, PZA                      MDR                       55    SM, INH, RFP, OFX, MFX, PZA                 XDR
  9     INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       56    SM, INH, RFP, CPM, OFX, MFX, PZA            XDR
  10    SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       57    SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR
  11    SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR                       58    INH, RFP, CPM, OFX, MFX, PZA                XDR
  12    SM, INH, RFP, KM, OFX, MFX, PZA             XDR                       59    SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR
  13    INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       60    RFP, CPM                                    DR
  14    SM, INH, RFP, EMB, CPM, KM, OFX, MFX        XDR                       61    INH, RFP                                    MDR
  15    INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       62    INH                                         DR
  16    SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       63    INH, RFP, LEV, OFX, MFX,                    MDR-plus
  17    SM, INH, RFP, CPM, KM, PZA                  MDR                       64    INH, RFP, LEV, OFX, MFX, KM, AMK, CPM       XDR
  18    INH, RFP, OFX, MFX, PZA                     MDR                       65    INH, RFP, LEV, OFX, MFX, KM, AMK, CPM       XDR
  19    INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       66    INH, RFP, OFX, KM                           XDR
  20    INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       67    RFP                                         DR
  21    INH, RFP, CPM, KM, MFX, PZA                 XDR                       68    INH, RFP,                                   MDR
  22    None detected                               S                         69    INH, RFP, CPM                               MDR-plus
  23    None detected                               S                         70    None detected                               S
  24    None detected                               S                         71    INH, RFP, LEV, OFX                          MDR-plus
  25    None detected                               S                         72    INH, RFP                                    MDR
  26    None detected                               S                         73    INH, RFP                                    MDR
  27    SM, INH, CPM, PZA                           DR                        74    INH, RFP                                    MDR
  28    INH                                         DR                        75    INH, RFP                                    MDR
  29    None detected                               S                         76    RFP, CPM                                    DR
  30    None detected                               S                         77    None detected                               DR
  31    None detected                               S                         78    INH, RFP, LEV, OFX, MFX, KM, AMK, CPM       XDR
  32    SM, INH, RFP, EMB, KM, OFX, MFX, PZA        XDR                       79    INH, RFP, LEV, OFX                          MDR-plus
  33    None detected                               S                         80    INH, RFP, LEV, OFX                          MDR-plus
  34    SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       81    CPM                                         DR
  35    None detected                               S                         82    INH, RFP, LEV, OFX                          MDR-plus
  36    None detected                               S                         83    None detected                               S
  37    INH                                         DR                        84    INH, RFP                                    MDR
  38    SM, INH, RFP, EMB, CPM, KM, MFX, PZA        XDR                       85    None detected                               S
  39    INH, RFP, EMB, OFX, MXF, PZA                MDR                       86    CPM                                         DR
  40    INH, RFP, CPM, KM, PZA                      MDR                       87    CPM                                         DR
  41    SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR                       88    None detected                               S
  42    SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       89    INH, RFP                                    MDR
  43    SM, INH, RFP, EMB, CPM, KM, PZA             MDR                       90    INH, RFP, MFX, CPM                          XDR
  44    SM, INH, RFP, CPM, KM, MFX, PZA             XDR                       91    INH, RFP, CPM                               MDR-plus
  45    SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       92    None detected                               S
  46    SM, INH, RFP, CPM, KM, OFX, MFX             XDR                       93    None detected                               S
  47    SM, INH, RFP, OFX, MFX, PZA                 MDR                                                                         

SM: streptomycin; INH: isoniazid; RFP: rifampicin; CPM: capreomycin; KM: kanamycin; OFX: ofloxacin; MFX: moxifloxacin; PZA: pyrazinamide; EMB: ethambutol; XDR: extensively drug-resistant; MDR: multidrug-resistant; S: susceptibility to all of the drugs; DR: drug resistance other than MDR (including MDR-plus and XDR); MDR-plus: INH+RFP+fluoroquinolone or INH+RFP+injectable drugs.

###### Isolates with *rpoC* mutations (n=24)

![](trd-81-222-i002)

  No.   Drug resistance                             Drug resistance profile   No.   Drug resistance                             Drug resistance profile
  ----- ------------------------------------------- ------------------------- ----- ------------------------------------------- -------------------------
  2     SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       50    INH, RFP, OFX, MFX, PZA                     MDR
  8     SM, INH, RFP, MFX, PZA                      MDR                       53    SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR
  9     INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       54    SM, INH, RFP, EMB, OFX, PZA                 XDR
  11    SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR                       57    SM, INH, RFP, EMB, CPM, KM, OFX, MFX, PZA   XDR
  13    INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       63    INH, RFP, LEV, OFX, MFX,                    MDR-plus
  16    SM, INH, RFP, CPM, KM, OFX, MFX, PZA        XDR                       65    INH, RFP, LEV, OFX, MFX, KM, AMK, CPM       XDR
  17    SM, INH, RFP, CPM, KM, PZA                  MDR                       71    INH, RFP, LEV, OFX                          MDR-plus
  20    INH, RFP, CPM, KM, OFX, MFX, PZA            XDR                       73    INH, RFP                                    MDR
  32    SM, INH, RFP, EMB, KM, OFX, MFX, PZA        XDR                       74    INH, RFP                                    MDR
  38    SM, INH, RFP, EMB, CPM, KM, MFX, PZA        XDR                       79    INH, RFP, LEV, OFX                          MDR-plus
  44    SM, INH, RFP, CPM, KM, MFX, PZA             XDR                       80    INH, RFP, LEV, OFX                          MDR-plus
  46    SM, INH, RFP, CPM, KM, OFX, MFX             XDR                       89    INH, RFP                                    MDR

Isolates with mutations in *rpoC* are resistant to both INH and RFP.

SM: streptomycin; INH: isoniazid; RFP: rifampicin; CPM: capreomycin; KM: kanamycin; OFX: ofloxacin; MFX: moxifloxacin; PZA: pyrazinamide; EMB: ethambutol; XDR: extensively drug-resistant; MDR-plus: INH+RFP+fluoroquinolone or INH+RFP+injectable drugs.

###### Mutations detected in the *rpoC* gene of 93 *Mycobacterium tuberculosis* isolates
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  Nucleotide change (nucleotide No.)   Translational change (codon No.)   Cultured isolates (n=93)   MDR-TB isolates (n=20)   XDR-TB isolates (n=36)   MDR-plus isolates (n=7)   DR isolates (n=12)   S isolates (n=18)   No.
  ------------------------------------ ---------------------------------- -------------------------- ------------------------ ------------------------ ------------------------- -------------------- ------------------- ---------------------------
  Substitution                                                                                                                                                                                                            
  843 A\>G                             I281V^\*^                          3 (3.23)                   2 (2.15)                 \-                       1 (1.08)                  \-                   \-                  71, 73, 89
  1249 A\>G                            N416S^\*^                          1 (1.08)                   \-                       1 (1.08)                 \-                        \-                   \-                  20
  1302 C\>A                            P434T^\*^                          1 (1.08)                   \-                       \-                       1 (1.08)                  \-                   \-                  79
  1338 C\>A                            L446M^\*^                          1 (1.08)                   \-                       \-                       1 (1.08)                  \-                   \-                  63
  1356 T\>C                            F452L                              7 (7.53)                   1 (1.08)                 6 (6.45)                 \-                        \-                   \-                  2, 11, 13, 17, 44, 53, 57
  1450 T\>C                            V483A                              1 (1.08)                   \-                       1 (1.08)                 \-                        \-                   \-                  38
  1450 T\>G                            V483G                              1 (1.08)                   \-                       1 (1.08)                 \-                        \-                   \-                  46
  1683 T\>C                            S561P\*                            1 (1.08)                   \-                       1 (1.08)                 \-                        \-                   \-                  54
  1726 C\>T                            A575V^\*^                          1 (1.08)                   \-                       1 (1.08)                 \-                        \-                   \-                  16
  2186 C\>T                            G728G^\*^                          1 (1.08)                   1 (1.08)                 \-                       \-                        \-                   \-                  74
  2242 A\>G                            D747G^\*^                          2 (2.15)                   1 (1.08)                 1 (1.08)                 \-                        \-                   \-                  8, 65
  2437 C\>T                            T812I^\*^                          1 (1.08)                   1 (1.08)                 \-                       \-                        \-                   \-                  50
  2441 G\>C                            Q813H^\*^                          1 (1.08)                   \-                       1 (1.08)                 \-                        \-                   \-                  32
  Multi-site mutations                 \-                                                                                                                                                                                 
  1683 T\>C, 1745 G\>A                 S561P^\*^, M581I^\*^               1 (1.08) M581I\*           \-                       1 (1.08)                 \-                        \-                   \-                  9
  1302, 1303 CC\>GT 2403A\>T           P434V, T801S^\*^                   1 (1.08)                   \-                       \-                       1 (1.08)                  \-                   \-                  80

Values are presented as number (%).

^\*^New mutation not reported in previous studies. Isolates with mutations in *rpoC* are resistant to both INH and RFP.

MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis; MDR-plus: INH+RFP+fluoroquinolone or INH+RFP+injectable drugs; DR: drug resistance other than MDR (including MDR-plus and XDR); S: susceptibility to all of the drugs; INH: isoniazid; RFP: rifampicin.
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